About Nuvectis Pharma, Inc.
https://www.nuvectis.comNuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases.
CEO
Ron Bentsur
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 42
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:698.71K
Value:$5.88M
BLACKROCK, INC.
Shares:685.34K
Value:$5.76M
RONIT CAPITAL LLP
Shares:562.55K
Value:$4.73M
Summary
Showing Top 3 of 56
About Nuvectis Pharma, Inc.
https://www.nuvectis.comNuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.79M ▲ | $-7.46M ▼ | 0% | $-0.44 ▼ | $-7.46M ▼ |
| Q2-2025 | $0 | $6.59M ▲ | $-6.33M ▼ | 0% | $-0.3 ▼ | $-6.33M ▼ |
| Q1-2025 | $0 | $5.57M ▼ | $-5.33M ▲ | 0% | $-0.27 ▲ | $-5.57M ▲ |
| Q4-2024 | $0 | $6.45M ▲ | $-6.25M ▼ | 0% | $-0.34 ▼ | $-6.45M ▼ |
| Q3-2024 | $0 | $4.36M | $-4.15M | 0% | $-0.24 | $-4.36M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $35.44M ▲ | $35.59M ▲ | $11.58M ▲ | $24.01M ▲ |
| Q2-2025 | $26.79M ▼ | $27.01M ▼ | $10.13M ▲ | $16.87M ▼ |
| Q1-2025 | $29.86M ▲ | $30.15M ▲ | $9.19M ▲ | $20.95M ▲ |
| Q4-2024 | $18.53M ▲ | $18.61M ▲ | $8.89M ▲ | $9.71M ▼ |
| Q3-2024 | $17.17M | $17.31M | $6.32M | $10.99M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.89M ▼ | $-4.49M ▼ | $0 | $13.14M ▲ | $8.65M ▲ | $-4.49M ▼ |
| Q2-2025 | $-6.33M ▼ | $-3.37M ▲ | $0 | $296K ▼ | $-3.07M ▼ | $-3.37M ▲ |
| Q1-2025 | $-5.33M ▲ | $-4.17M ▼ | $0 | $15.51M ▲ | $11.33M ▲ | $-4.17M ▼ |
| Q4-2024 | $-6.25M ▼ | $-2.46M ▼ | $0 | $3.83M ▲ | $1.36M ▲ | $-2.46M ▼ |
| Q3-2024 | $-4.15M | $-2.4M | $0 | $1.46M | $-947K | $-2.4M |
CEO
Ron Bentsur
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 42
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:698.71K
Value:$5.88M
BLACKROCK, INC.
Shares:685.34K
Value:$5.76M
RONIT CAPITAL LLP
Shares:562.55K
Value:$4.73M
Summary
Showing Top 3 of 56